Covariate‐adjusted borrowing of historical control data in randomized clinical trials

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Pharmaceutical statistics

• Publication date

  2017-05-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/pst.1815PMID 28560815
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Combining non-randomized and randomized data in clinical trials using commensurate priors

  2016cited by this paper
• COMBINING NONEXCHANGEABLE FUNCTIONAL OR SURVIVAL DATA SOURCES IN ONCOLOGY USING GENERALIZED MIXTURE COMMENSURATE PRIORS.

  2015cited by this paper
• Do single‐arm trials have a role in drug development plans incorporating randomised trials?

  2015cited by this paper
• Use of historical control data for assessing treatment effects in clinical trials

  2014cited by this paper
• The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies

  2014cited by this paper
• Semiparametric Bayesian commensurate survival model for post‐market medical device surveillance with non‐exchangeable historical data

  2014cited by this paper
• Bayesian approach for flexible modeling of semicompeting risks data

  2014cited by this paper
• Adaptive adjustment of the randomization ratio using historical control data

  2013cited by this paper
• Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.

  2013cited by this paper
• Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

  2012cited by this paper
• Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models.

  2012cited by this paper
• New considerations in the design of clinical trials for amyotrophic lateral sclerosis.

  2011cited by this paper
• Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials

  2011cited by this paper
• REPORT BY THE DECISION SUPPORT UNIT

  2010cited by this paper
• Bayesian Adaptive Methods for Clinical Trials

  2010cited by this paper
• The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee

  2010cited by this paper
• A note on the power prior

  2009cited by this paper
• Committee for Proprietary Medicinal Products (CPMP)

  2009cited by this paper
• The BUGS project: Evolution, critique and future directions

  2009cited by this paper
• Randomized Phase II Designs

  2009cited by this paper
• Prognostic factors in ALS: A critical review

  2009cited by this paper
• Determining the Effective Sample Size of a Parametric Prior

  2008cited by this paper
• Meta‐analysis of continuous outcomes combining individual patient data and aggregate data

  2008cited by this paper
• Incident reporting and patient safety

  2007cited by this paper
• Experience with Reviewing Bayesian Medical Device Trials

  2007cited by this paper
• The relationship between the power prior and hierarchical models

  2006cited by this paper
• Predictability of disease progression in amyotrophic lateral sclerosis

  2006cited by this paper
• Committee for Proprietary Medicinal Products (CPMP): points to consider on adjustment for baseline covariates.

  2004cited by this paper
• Prior distributions for variance parameters in hierarchical models (comment on article by Browne and Draper)

  2004cited by this paper
• SAMPLE SIZE CALCULATION FOR A HISTORICALLY CONTROLLED CLINICAL TRIAL WITH ADJUSTMENT FOR COVARIATES

  2002cited by this paper
• Power prior distributions for generalized linear models

  2000cited by this paper
• Dose-ranging study of riluzole in amyotrophic lateral sclerosis

  1996cited by this paper
• Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II.

  1996cited by this paper
• The central role of the propensity score in observational studies for causal effects

  1983cited by this paper
• The combination of randomized and historical controls in clinical trials.

  1976cited by this paper

• Probability of Success for Establishing Noninferiority Across Multiple Visits: Extension of Covariate‐Adjusted Bayesian Hierarchical Modeling Framework

  2026cites this paper
• Bayesian analysis of the rate of spontaneous malignant mesothelioma among BAP1 mutant mice in the absence of asbestos exposure

  2025cites this paper
• Commensurate prior models with random effects for interval-censored data to accommodate historical controls

  2025cites this paper
• Adaptive Constrained Weighted Estimation for Incorporating Multiple External Information Sources

  2025cites this paper
• Augmenting the Control Arm of Randomized Trials by Incorporating Multiple External Data Sources Using Propensity Score Stratification and Data-Driven Mixture Prior

  2025cites this paper
• Real-World Data and Causal Machine Learning to Enhance Drug Development

  2025cites this paper
• A Commensurate Prior Model With Random Effects for Survival and Competing Risk Outcomes to Accommodate Historical Controls

  2025cites this paper
• Borrowing from historical control data in a Bayesian time-to-event model with flexible baseline hazard function

  2024cites this paper
• Nonparametric Bayesian approach for dynamic borrowing of historical control data.

  2024cites this paper
• BayesFBHborrow: An R Package for Bayesian borrowing for time-to-event data from a flexible baseline hazard

  2024cites this paper
• A novel Phase II single-arm hybrid design to minimize trial duration and enhance subsequent Phase III trial success rate

  2024cites this paper
• Borrowing Historical Information Across All Concentration Groups with an Application of Potency Estimation in Aquatic Toxicity Assessment

  2024cites this paper
• Identification and Estimation of Causal Effects Using Non‐Concurrent Controls in Platform Trials

  2024cites this paper
• Covariate adjusted meta-analytic predictive (CA-MAP) prior for historical borrowing using patient-level data

  2024cites this paper
• Decoupling power and type I error rate considerations when incorporating historical control data using a test‐then‐pool approach

  2024cites this paper
• Leveraging external evidence using Bayesian hierarchical model and propensity score in the presence of covariates.

  2023cites this paper
• Predicting Probability of Success for Phase III Trials via Propensity-Score-Based External Data Borrowing

  2023cites this paper
• Dynamic use of historical controls in clinical trials for rare disease research: A re-evaluation of the MILES trial

  2023cites this paper
• Semiparametric pseudo‐score and pseudo‐likelihood for evaluating correlate of protection in vaccine trials

  2023cites this paper
• Augmenting Treatment Arms With External Data Through Propensity‐Score Weighted Power Priors: An Application in Expanded Access

  2023cites this paper
• Bayesian Prognostic Covariate Adjustment With Additive Mixture Priors

  2023cites this paper
• On the use of non-concurrent controls in platform trials: a scoping review

  2022cites this paper
• Matching design for augmenting the control arm of a randomized controlled trial using real-world data

  2022influential citation
• Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls.

  2022cites this paper
• Bayesian adaptive randomization design incorporating propensity score‐matched historical controls

  2022cites this paper
• Using horseshoe prior for incorporating multiple historical control data in randomized controlled trials

  2022cites this paper
• Bayesian Design of Superiority Trials: Methods and Applications

  2022cites this paper
• Evaluating hybrid controls methodology in early‐phase oncology trials: A simulation study based on the MORPHEUS‐UC trial

  2022cites this paper
• External Comparator Groups Derived from Real-world Data Used in Support of Regulatory Decision Making: Use Cases and Challenges

  2022cites this paper
• Challenges of using external data in clinical trials- an illustration in patients with COVID-19

  2022cites this paper
• The power prior with multiple historical controls for the linear regression model

  2021cites this paper
• A group‐sequential randomized trial design utilizing supplemental trial data

  2021cites this paper
• Flexible Conditional Borrowing Approaches for Leveraging Historical Data in the Bayesian Design of Superiority Trials

  2021cites this paper
• Propensity‐score‐based meta‐analytic predictive prior for incorporating real‐world and historical data

  2021cites this paper
• A flexible Bayesian framework for individualized inference via adaptive borrowing.

  2021cites this paper
• Historical Controls in Randomized Clinical Trials: Opportunities and Challenges

  2020cites this paper
• Real-World Evidence Utilization in Clinical Development Reflected by US Product Labeling: Statistical Review

  2020cites this paper
• Leveraging historical data into oncology development programs: Two case studies of phase 2 Bayesian augmented control trial designs

  2020influential citation
• Methods for external control groups for single arm trials or long‐term uncontrolled extensions to randomized clinical trials

  2020cites this paper
• Summarising salient information on historical controls: A structured assessment of validity and comparability across studies

  2020cites this paper
• Enhancing single-arm phase II trials by inclusion of matched control patients

  2020cites this paper
• Suitability of external controls for drug evaluation in Duchenne muscular dystrophy

  2020cites this paper
• Methods for Using Aggregate Historical Control Data in Meta-Analyses of Clinical Trials With Time-to-Event Endpoints

  2020cites this paper
• Dynamic borrowing in the presence of treatment effect heterogeneity.

  2020cites this paper
• Reducing Patient Burden in Clinical Trials Through the Use of Historical Controls: Appropriate Selection of Historical Data to Minimize Risk of Bias

  2019cites this paper